Selank and Immune Function Research: Th1/Th2 Immunomodulation, Cytokine Biology and Autoimmune Mechanisms UK 2026

Research Use Only. Selank is not licensed as an immunomodulatory agent in the UK outside of approved clinical contexts. All content describes preclinical and investigational research biology. Not medical advice.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, a heptapeptide analogue of the immunomodulatory peptide Tuftsin Thr-Lys-Pro-Arg) was originally developed for its anxiolytic and nootropic properties but possesses a parallel and clinically relevant immunological profile. Tuftsin — the parent tetrapeptide — is a phagocytosis-stimulating factor derived from IgG heavy chain cleavage. Selank’s Pro-Gly-Pro extension (identical to that of Semax) confers enzymatic stability while preserving and extending the immunomodulatory activity of the parent Tuftsin sequence. This post examines Selank’s mechanisms in T cell biology, cytokine regulation, and autoimmune research models.

Tuftsin-Derived Receptor Biology

Tuftsin (and by extension Selank’s Tuftsin-homologous domain) engages a cell surface receptor on phagocytes, lymphocytes, and NK cells — historically termed the “Tuftsin receptor” — that activates PI3K-Akt and PKC signalling, promoting phagocytosis, respiratory burst (NADPH oxidase activation), and cytokine production. More recently, the neuropilin-1 (NRP-1) receptor on macrophages and T cells has been identified as a candidate Tuftsin-interacting surface molecule, with downstream effects on NF-κB activation and Treg-Teff balance (NRP-1 is preferentially expressed on Tregs and its engagement by Tuftsin-homologous sequences may modulate Treg function).

The Pro-Gly-Pro (PGP) extension additionally engages chemokine receptor CXCR2 on neutrophils (PGP is an endogenous neutrophil chemoattractant produced from collagen degradation), contributing anti-fibrotic and resolution-promoting activity in inflammatory contexts. CXCR2 antagonist SB225002 or MK-7123 controls in Selank immune studies dissect PGP-CXCR2 from Tuftsin-mediated immune effects.

Th1/Th2 Balance Modulation

Th1/Th2 immune polarisation is a fundamental organising principle of adaptive immunity: Th1 cells (IFN-γ, TNF-α, IL-12-driven) mediate cellular immunity against intracellular pathogens and underlie autoimmune tissue destruction; Th2 cells (IL-4, IL-5, IL-13-driven) mediate humoral immunity and contribute to allergic disease. Many chronic inflammatory and autoimmune conditions involve aberrant Th1 dominance (rheumatoid arthritis, type 1 diabetes, EAE/MS) or Th2 dominance (allergy, atopic conditions).

Selank exerts bidirectional Th balance modulation depending on baseline immune state: in Th1-polarised inflammatory conditions, Selank reduces IFN-γ and IL-12p70 production (ELISA from splenocyte or PBMC supernatants following mitogen/antigen stimulation, ConA or anti-CD3/CD28) and increases IL-4 and IL-10 production, shifting the Th1:Th2 ratio toward Th2/regulatory. In Th2-dominant (allergic) settings, Selank reduces IL-4, IL-5, and IL-13 while supporting IFN-γ — a bidirectional immune-balancing effect that is mechanistically consistent with a homeostatic immunomodulator rather than a unidirectional suppressor.

Flow cytometry intracellular cytokine staining (ICS): PMA/ionomycin stimulation (4h + BFA 2h) → fixation/permeabilisation (BD Cytofix/Cytoperm) → anti-IFN-γ FITC + anti-IL-4 PE + anti-CD4 APC + anti-CD8 PerCP → % CD4+IFN-γ+ (Th1) vs % CD4+IL-4+ (Th2) cells. Selank dose-response (0.1–100 µg/ml in culture or 0.1–1 mg/kg i.p. in vivo followed by ex vivo ICS) with cytokine ratio calculation enables Th balance quantification.

NK Cell Biology

Natural killer (NK) cells mediate innate immune surveillance of virus-infected and transformed cells without prior sensitisation. Tuftsin enhances NK cell cytotoxicity against K562 target cells (51Cr-release assay or calcein-AM fluorescent target cytotoxicity assay, effector:target ratios 5:1–40:1). Selank similarly enhances NK cytotoxic activity in splenocytes from immunosuppressed mice (cyclophosphamide-treated, 150 mg/kg i.p. day -2) — an immunosuppression model where NK function is compromised. NK cytotoxicity restoration (%lysis at E:T 20:1) and NK cell degranulation (CD107a surface mobilisation by flow, LAMP-1 ICS) are endpoint measures. Granzyme B expression (intracellular staining) and perforin release (perforin ELISA from NK cell supernatants) quantify the cytolytic machinery.

Macrophage Polarisation Research

Tuftsin receptor activation on macrophages stimulates phagocytic index (fluorescent latex bead or opsonised SRBC uptake, phagocytic index = % phagocytic cells × mean beads per cell, confocal or flow cytometry). Selank at 1–100 µg/ml enhances BMDM (bone marrow-derived macrophage) phagocytic index in unstimulated and LPS-primed conditions. M1 polarisation markers after LPS+IFN-γ (IL-12p70, TNF-α, iNOS, CD80, CD86) are dose-dependently reduced by Selank, while M2 markers (IL-10, arginase-1, CD206/MRC1, TGF-β1) are enhanced — consistent with the immunomodulatory homeostatic profile.

NLRP3 inflammasome: Selank’s NF-κB suppressive effects (IKKβ-IκBα-p65 nuclear translocation inhibition, western/EMSA/luciferase reporter) downstream of TLR4-MyD88 reduce NLRP3-ASC-caspase-1 priming and activation signal (two-signal model: LPS priming + ATP/nigericin/MSU activation). Caspase-1 p20 cleavage western, IL-1β p17 secretion ELISA, and LDH pyroptosis assay quantify NLRP3 inflammasome endpoints in macrophages ± Selank.

Regulatory T Cell Biology

CD4+CD25+FoxP3+ regulatory T cells (Tregs) suppress autoimmune and excessive inflammatory responses through IL-10, TGF-β1, and cell-contact CTLA-4/PD-L1 mechanisms. Treg expansion or functional enhancement is a research-relevant anti-autoimmune strategy. Selank (via NRP-1 engagement on Tregs and IL-10 upregulation) may promote Treg-Teff balance. In vitro: Treg suppression assay (CFSE-labelled Teff proliferation after anti-CD3 stimulation + Treg co-culture at 1:1 to 1:8 Treg:Teff ratios ± Selank, % CFSE dilution by flow); FoxP3 IHC/flow in draining lymph nodes and spleen at sacrifice in autoimmune model.

Autoimmune Disease Research Models

EAE (experimental autoimmune encephalomyelitis): The primary preclinical MS model. C57BL/6 mice immunised with MOG₃₅₋₅₅ peptide in CFA + pertussis toxin develop ascending motor paralysis (EAE clinical score 0–5 scale) driven by myelin-reactive CD4+ Th1/Th17 cells invading the spinal cord. Selank (0.1–1 mg/kg/day i.p. from day 1 post-immunisation or from disease onset day 10): clinical score daily scoring, spinal cord CD4+/CD8+ T cell infiltration (IHC, flow from CNS digests), Iba1+ microglia/macrophage activation, demyelination (Luxol Fast Blue, myelin basic protein MBP IHC), and Th1/Th17 (IFN-γ/IL-17A ICS) vs Treg (FoxP3+) ratio in draining LN and spinal cord.

Collagen-induced arthritis (CIA): Wistar rats or DBA/1J mice immunised with type II collagen in CFA (boost at day 21 in IFA) develop erosive polyarthritis in hindpaws by day 28–35. CIA is Th1-driven with TNF-α, IL-6, and IL-17 mediating synovial inflammation and cartilage/bone destruction. Selank endpoints: arthritis index (0–16 scale, 4 limbs × 4-point score for swelling/erythema), paw volume (plethysmometry), histopathological joint score (H&E: synovial hyperplasia, pannus, cartilage erosion; Safranin-O for proteoglycan loss), serum anti-CII IgG titres (ELISA), and synovial fluid cytokine multiplex (TNF-α, IL-1β, IL-6, IL-17A).

Type 1 diabetes (T1D) prevention: NOD (non-obese diabetic) mouse model of spontaneous autoimmune β-cell destruction (30–80% female incidence by week 30). Selank administered from week 4 to week 20 (before disease onset): blood glucose monitoring (weekly, diabetes threshold ≥200 mg/dl × 2 consecutive readings), insulitis score (pancreatic sections H&E, periisletitis vs intraisletitis grading 0–4), and residual β-cell mass (insulin IHC, islet area fraction). Mechanistic endpoint: pancreatic-draining lymph node Treg:Teff ratio and IFN-γ/IL-10 balance.

Immunosuppression Recovery Research

Cyclophosphamide (CY, 150–200 mg/kg i.p.) produces profound leukopenia (neutropenia, lymphopenia, NK depletion) within 3–5 days — a clinically relevant model of chemotherapy-induced immunosuppression. Selank administered from day 1 post-CY through day 14 accelerates haematopoietic recovery: peripheral blood CBC (WBC, neutrophil, lymphocyte absolute counts at days 3/7/10/14); bone marrow CFU-GM (granulocyte-macrophage colony forming unit) assay (methylcellulose culture, colonies counted at day 14); NK cytotoxicity restoration (K562 calcein assay at day 7 and 14); and T cell mitogenic response (ConA splenocyte proliferation ³H-thymidine incorporation).

Summary

Selank’s immunological profile — rooted in its Tuftsin-homologous domain with PGP extension — encompasses bidirectional Th1/Th2 homeostatic modulation, NK cell cytotoxicity enhancement, macrophage M1→M2 polarisation shift, NF-κB-NLRP3 inflammasome suppression, and Treg-Teff balance support. In autoimmune research (EAE, CIA, NOD-T1D), these properties translate to reduced disease severity, diminished autoreactive T cell infiltration, and improved Treg:Teff balance. In immunosuppression recovery (CY model), accelerated haematopoietic and NK function restoration is documented. Research designs must include CXCR2 antagonist controls (PGP-mediated effects), NRP-1 pathway verification, and flow cytometric ICS panels for mechanistically resolved Th/Treg quantification.